Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
| 13.47 Delayed Data As of Jun 29 |  +0.11 / +0.82%Today’s Change | 6.51 Today|||52-Week Range 37.99 | +37.87% Year-to-Date |
Latest DCPH News | Press Releases
| Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry Jun 17 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 13.35 |
| Today’s open | 13.01 |
| Day’s range | 13.01 - 13.53 |
| Volume | 596,736 |
| Average volume (3 months) | 1,266,326 |
| Market cap | $911.1M |
Data as of 3:59pm ET, 06/29/2022
Growth & Valuation
| Earnings growth (last year) | -8.10% |
| Earnings growth (this year) | +48.45% |
| Earnings growth (next 5 years) | +21.00% |
| Revenue growth (last year) | +128.45% |
| P/E ratio | NM |
| Price/Sales | 5.90 |
| Price/Book | 2.64 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| QUREUniqure NV | -0.10 | -0.54% |
| EDITEditas Medicine Inc | -0.22 | -1.77% |
| RCKTRocket Pharmaceutica... | +0.16 | +1.24% |
| REPLReplimune Group Inc | +0.29 | +1.69% |
Data as of 4:00pm ET, 06/29/2022
Financials
| Next reporting date | August 9, 2022 |
| EPS forecast (this quarter) | -$0.66 |
| Annual revenue (last year) | $96.1M |
| Annual profit (last year) | -$300.0M |
| Net profit margin | -311.98% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Waltham, Massachusetts |
Forecasts
